Lisa Schapink

Lisa Schapink

Auto-generated profile, based on publicly available information

Lisa Schapink

Department of Rheumatology, Sint Maartenskliniek , Nijmegen

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 January 2024 in Rheumatology International
Verified
Journal Article
Closed access
PDF file
LSLisa Schapink
Lisa Schapink
NBNathan Den Broeder
Nathan Den Broeder
ABAlfons A. Den Broeder
Alfons A. Den Broeder
LVLise Verhoef
Lise Verhoef

12 August 2025 in Clinical Infectious Diseases
Verified
Journal Article
Closed access
MOMerel A A Opdam
Merel A A Opdam
NBNathan Den Broeder
Nathan Den Broeder
RCReinout Van Crevel
Reinout Van Crevel
LSLisa Schapink
Lisa Schapink
LRLeon Raymakers
Leon Raymakers
ABAlfons A Den Broeder
Alfons A Den Broeder
Background: Immunomodulatory agents (IA) are commonly used to treat inflammatory rheumatic diseases (IRDs). Guidelines typically recommend temporarily interrupting IA during infections, but evidence supporting this approach is limited and continuation may be equally safe or even preferable. The objective of this study was to compare these 2 treatment strategies. Methods: We conducted a large multi-center, open-label, randomized controlled trial (Dutch Trial Register (NL8922), in which infection-free IRD patients on IA were randomized 1:1 to either continue or temporarily interrupt IA treatment when experiencing their first clinically relevant infection. Primary outcome was the proportion of patients with a serious infection (requiring hospitalization or intravenous treatment), analyzed in the modified intention-to-treat (mITT) population using the Cochran-Mantel-Haenszel method. The mITT population included all patients who experienced a clinically relevant infection during follow-up. Secondary analyses included Complier Average Causal Effect (CACE) models to account for non-adherence. Results: Of 1142 patients enrolled (1667 patient years of follow-up), 474 developed a clinically relevant infection (mITT population). Serious infections occurred in 12 of 233 patients (5.15%) in the interruption group and in 9 of 241 (3.73%) in the continuation group, adjusted risk difference was 1.71% (95% CI −1.99 to 5.39). CACE analysis showed a risk difference of 4.51 (95% confidence interval [CI]: −7.32 to 16.34) in favor of continuation. Conclusions: These findings suggest that temporary interruption and continuation of IA result in similar risk and outcome of infections in IRD patients. Although his study is limited by low statistical power, the findings suggest that continuation of IA during an infection is safe.